Blueshift Asset Management LLC Cuts Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Blueshift Asset Management LLC reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 55.3% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,368 shares of the company’s stock after selling 22,718 shares during the quarter. Blueshift Asset Management LLC’s holdings in Teva Pharmaceutical Industries were worth $405,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TEVA. Oppenheimer & Co. Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 68.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 32,402 shares of the company’s stock worth $584,000 after buying an additional 13,215 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,218 shares during the period. Pathstone Holdings LLC raised its stake in Teva Pharmaceutical Industries by 6.5% in the 3rd quarter. Pathstone Holdings LLC now owns 72,598 shares of the company’s stock valued at $1,308,000 after acquiring an additional 4,452 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $455,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $14,840,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 0.2 %

TEVA stock opened at $16.27 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company’s 50 day moving average is $17.88 and its 200 day moving average is $18.23. The stock has a market cap of $18.44 billion, a price-to-earnings ratio of -11.22, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TEVA shares. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday. UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Finally, Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.